Febuxostat Therapy for Patients With Stage 3 CKD and Asymptomatic Hyperuricemia: A Randomized Trial
ConclusionsCompared to placebo, febuxostat did not mitigate the decline in kidney function among patients with stage 3 CKD and asymptomatic hyperuricemia.FundingFunded by Teijin Pharma Limited.Trial RegistrationRegistered at the UMIN (University Hospital Medical Information Network) Clinical Trials Registry with study number UMIN000008343.
Source: American Journal of Kidney Diseases - Category: Urology & Nephrology Source Type: research
More News: Arthritis | Chronic Kidney Disease | Clinical Trials | Dialysis | Japan Health | Pharmaceuticals | Proteinuria | Rheumatology | Study | Urology & Nephrology